This is a Phase 1 clinical study for adults 18 years and older with mild to moderate Psoriasis plaques. The study will test a new medication called SFA002 to see how safe and effective it is at different dosages.
What to Expect
Participants will be randomly assigned to one of two groups that will receive the medication at different dosages. Neither participants nor the researchers will know who is in which group during the study.
Treatment Period
- 24 weeks
Trial Requirements
- Age 18+
Urgently Recruiting
Trial Details
The purpose of this study is to determine the safety, metabolism and potential effect of drug product SFA-002 on mild moderate and severe chronic plaque psoriasis.
Up to ninety volunteers with mild to moderate chronic plaque psoriasis will be recruited for an open label 24 week prospective study of the safety of 2 different dosages for 12 weeks of active therapy and 12 weeks of follow up. Blood will be drawn to determine any clinical effect on each group at the 12 week time mark and residual effects after 24 weeks. Throughout the study the investigators will perform both clinical and laboratory assessments to measure safety and response.
